Emergent Biosolutions Inc. (EBS) said Abbott Laboratories (ABT) will terminate its co-development and co-commercialization agreement for the TRU-016 drug, as Abbott told the biopharmaceutical company it is changing its portfolio priorities.TRU-016 is a potential treatment of B-cell malignancies, including chronic lymphocytic leukemia and non-Hodgkin's lymphoma, as well as for autoimmune and inflammatory diseases, according to the National Institutes of Health.
Wednesday, December 28, 2011
Abbott to drop work on cancer treatment - chicagotribune.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment